<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2228">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132153</url>
  </required_header>
  <id_info>
    <org_study_id>FAMSU R 174/2021</org_study_id>
    <nct_id>NCT05132153</nct_id>
  </id_info>
  <brief_title>Effect of Nebulized Milrinone on Right Ventricular Hemodynamics in Adult Cardiac Surgery</brief_title>
  <official_title>Effect of Nebulized Milrinone on Right Ventricular Hemodynamics in Adult Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study was to investigate the effect inhaled milrinone given before&#xD;
      CPB on improving the right ventricular function measured by transesophageal echocardiography&#xD;
      (TEE) at time of CPB separation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will include (70) patients planned for elective adult cardiac surgery&#xD;
      (Coronary revascularization surgery, Mitral valve surgery, Aortic valve surgery or complex&#xD;
      surgery (either two or more valves or valves and coronary revascularization surgery). All&#xD;
      surgery should be with CPB. All patients will be diagnosed with preoperative PH. After&#xD;
      separation of CPB the patients evaluated as regard the hemodynamics (MAP, HR), the inotropic&#xD;
      score as additional intravenous milrinone in the case of low cardiac output or presence of&#xD;
      post-CPB PH or RV failure with reduced contractility documented using TEE. Left ventricular&#xD;
      EF, and right ventricular hemodynamics represented by RV function measured by (tricuspid&#xD;
      annulus plane systolic excursion (TAPSE), fractional area change FAC), and right ventricular&#xD;
      systolic pressure by doppler (RVSP) which represent the pulmonary artery pressure all data&#xD;
      will be assessed by transesophageal ECHO after anesthesia, immediately before CPB and&#xD;
      immediately after separation from CPB all these data will be recorded in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2021</start_date>
  <completion_date type="Anticipated">January 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of inhaled milrinone on improvement of right ventricular function</measure>
    <time_frame>After 15 minutes of inhaled milrinone intraoperative and repeated after 12, 24 hours in intensive care unit</time_frame>
    <description>The right ventricle function will be assessed by Fractional area change ( Change in area between systole and diastole by echocardiograph ( intraoperative and postoperative)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>(Group A) will receive milrinone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive milrinone 50 microgram/kg in 5ml volume, over 5 min by nebulization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Group B) will receive normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 5 ml saline by nebulization over 5 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milrinone</intervention_name>
    <description>will be given by nebulization</description>
    <arm_group_label>(Group A) will receive milrinone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>will be given by nebuliztion</description>
    <arm_group_label>(Group B) will receive normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility criteria:&#xD;
&#xD;
          -  elective adult cardiac surgery (Coronary revascularization surgery, Mitral valve&#xD;
             surgery, Aortic valve surgery or complex surgery (either two or more valves or valves&#xD;
             and coronary revascularization surgery).&#xD;
&#xD;
          -  All surgery should be with CPB.&#xD;
&#xD;
          -  All patients will be diagnosed with preoperative PH. PH was defined as a mean&#xD;
             pulmonary artery pressure (MPAP) 30 mmHg or a systolic pulmonary artery pressure&#xD;
             (SPAP) 40 mmHg, measured during preoperative right-sided catheterization or estimated&#xD;
             by using doppler transthoracic echocardiography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac surgery without CPB.&#xD;
&#xD;
          -  Hemodynamic instability in the preoperative time (defined as acute requirement for&#xD;
             vasoactive support or mechanical device).&#xD;
&#xD;
          -  Adult congenital heart disease planned for corrective surgery.&#xD;
&#xD;
          -  Contraindication to transesophageal echocardiography (TEE).&#xD;
&#xD;
          -  Any surgery involves tricuspid valve annulus as it will compromise the accuracy of RV&#xD;
             function assessment by TEE.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samar Soliman</last_name>
    <phone>01006236494</phone>
    <email>dr_sm.md@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samar Soliman</name>
      <address>
        <city>Cairo</city>
        <state>Nasr City</state>
        <zip>11511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samar Soliman</last_name>
      <phone>01006236494</phone>
      <email>dr_sm.md@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>samar mohammed</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milrinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

